Securities code: China Meheco Group Co.Ltd(600056) securities abbreviation: China Meheco Group Co.Ltd(600056) Announcement No.: Lin 2022009
China Meheco Group Co.Ltd(600056)
Announcement of abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
China Meheco Group Co.Ltd(600056) (hereinafter referred to as “the company” or “the company”) has accumulated more than 20% deviation from the daily closing price increase within three consecutive trading days on March 9, 2022, March 10, 2022 and March 11, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it is an abnormal fluctuation in stock trading.
After the company’s self-examination and verification with the controlling shareholder and actual controller, there are no major matters that should be disclosed but not disclosed.
The company signed an agreement with Pfizer on March 9, 2022 and issued Lin 2022007 announcement on signing an agreement with Pfizer on March 10. The company will be responsible for Pfizer covid-19 virus treatment drug paxlovid during the agreement period (2022) ™ (hereinafter referred to as “product”) in the Chinese mainland market business operation. On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. This product is a prescription drug, which has not yet entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent business performance.
1、 Details of abnormal fluctuations in stock trading
The deviation of the daily closing price of the company’s shares in three consecutive trading days on March 9, 2022, March 10, 2022 and March 11, 2022 exceeds 20% in total. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to abnormal fluctuation of stock trading.
2、 Relevant information concerned and verified by the company
(I) production and operation
According to the company’s self inspection, the company’s current production and operation activities are normal, and there are no major events affecting the abnormal fluctuation of the company’s stock trading price.
(II) major events
According to the reply from China General Technology (Group) Holding Co., Ltd., the controlling shareholder of the company, the controlling shareholder and the actual controller of the company do not have any major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase Bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major issues. (III) media reports, market rumors and hot concepts
The company signed an agreement with Pfizer on March 9, 2022. The company will be responsible for Pfizer covid-19 virus treatment drug paxlovid during the agreement period (2022) ™ Business operation in the Chinese mainland market. On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. This product is a prescription drug, which has not yet entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent business performance.
In addition to the above related matters, the company has not found any other media reports, market rumors and hot concepts that may have a great impact on the trading price of the company’s shares.
(IV) other stock price sensitive information. It is verified that during the abnormal fluctuation period of the above stock trading, the company’s directors, supervisors, senior managers and controlling shareholders did not buy or sell the company’s shares, and the company did not find any other major events that may have a great impact on the company’s share price.
3、 Relevant risk tips
(I) secondary market transaction risk
The company’s shares have increased significantly from March 2, 2022 to March 11, 2022. The company has issued Lin 2022004 announcement on abnormal fluctuation of stock trading price, Lin 2022005 announcement on risk warning and Lin 2022006 announcement on abnormal fluctuation of stock trading price on March 4, March 5 and March 8, 2022 respectively. In view of the large fluctuation range of the company’s share price, please pay attention to the transaction risk of the secondary market, make rational decisions and invest prudently.
(II) production and operation risks
The company’s main business segments include pharmaceutical industry, pharmaceutical commerce and international trade, and there are no significant changes. At present, the company’s production and operation activities are normal, and there are no major matters affecting the abnormal fluctuation of the company’s stock trading price. (III) risk tips for cooperation with Pfizer
The company signed an agreement with Pfizer on March 9, 2022. The company will be responsible for Pfizer covid-19 virus treatment drug paxlovid during the agreement period (2022) ™ Business operation in mainland China market. On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. This product is a prescription drug, which has not yet entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent business performance.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules or the planning, negotiation, intention and agreement related to the matters, and the board of directors has not been informed that the company has matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules Information that has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
The media of the information disclosure website designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN.) And Shanghai Securities News, China Securities News, securities times and Securities Daily. Relevant information shall be subject to the announcements published by the company on the above designated websites and media. Please invest rationally and pay attention to investment risks. It is hereby announced.
China Meheco Group Co.Ltd(600056) board of directors March 12, 2022
